Mirvie

Active#8 worldwide · In-vitro diagnostics

Estimated valuation · In-vitro diagnostics · United States

Develops pregnancy blood tests that analyse cell-free RNA to predict complications such as preeclampsia and preterm birth before symptoms appear.

Healthtech›In-vitro diagnostics mirvie.com

HQUnited States

Last roundSeries B · May 2022

Estimated valuation

AI · In-vitro diagnostics ranking (worldwide)

≈ USD 310MUSD 210–460M · Hundreds of M$

Hundreds of k$

Millions $

Tens of M$

Hundreds of M$

Unicorn

Decacorn

Hectocorn

Anchor: Last known equity round: Series B · USD 60M · May 2022

An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method

Uback rankings

How the AI ranks →

Ranking	Tier	Rank	Edition	Next update
In-vitro diagnostics · worldwide	Top 25	#8	Edition 0 · Oct 2026	12 Apr 2027

Rank historyOct 2026 · #8 In-vitro diagnosticsFirst edition: no movements yet.

Funding history

Date	Round	Amount	Type	Investors
May 2022	Series B	USD 60M	Equity	Decheng Capital, Foresite Capital, General Catalyst, GV

Rounds as cited by Uback’s rankings. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of Mirvie as a PDF. It must answer at least one of these four questions, and stick to them:

AI valuation: $310MUndervalued or overvalued?

Versus competitorsHow does it compare?

Who should acquire itStrategic buyers, and why

Who should it acquireAcquisition targets, and why

Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication.

Invest

Back Mirvie whether or not it has agreed: your intention joins the pool on Mirvie, passed to the Fundraising Desk of its country once it reaches critical mass. Backing on Uback (pronounced “you back”) means declaring an Interest (free) or an Intention (coming soon). Backing does not mean that this company is raising funds or that a shareholder is selling shares, and it is not a commitment to invest. Any deal, through a funding round or a sale by an existing shareholder, is handled by a partner desk: the Fundraising Desk of the country for a round, the Secondary Sales Desk assigned to the company for a sale.

Back Mirvie Or back healthtech in United States

Pool on MirvieBelow threshold

BackersBelow threshold

Paid intention · valid for life · movable until you sign with a partner desk. If the company does not follow up, Uback invites its Backers to move their intentions to a competitor or a similar company. Investing in non-listed companies carries a risk of losing all the capital invested.

Do you run Mirvie?

Claim this profile to correct data, add your logo and description, or tell Uback about an upcoming round.

Claim this profile Report an upcoming round → Report an error →

Are you a shareholder?

Considering selling some of your shares? Tell Uback privately. Nothing is published without your consent, and never a price or a volume.

Tell Uback privately

What the AI reads

Read by the AI at the next edition.

Comparable companies in in-vitro diagnostics

Full in-vitro diagnostics ranking →

Truvian Health#7United StatesHundreds of M$Inflammatix#9United StatesHundreds of M$Karius#6United StatesHundreds of M$deepull#10SpainHundreds of M$

Last updated: Oct 2026Report an error

Uback is a content publisher and an aggregator of non-binding expressions of interest. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.